Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Helen, Booler"'
Autor:
Doha Naga, Smaragda Dimitrakopoulou, Sonia Roberts, Elisabeth Husar, Susanne Mohr, Helen Booler, Eunice Musvasva
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-16 (2023)
Abstract In-vivo toxicity assessment is an important step prior to clinical development and is still the main source of data for overall risk assessment of a new molecular entity (NCE). All in-vivo studies are performed according to regulatory requir
Externí odkaz:
https://doaj.org/article/29caf756a49742ddb010ee163c88d7a3
Autor:
Peter M. Maloca, Christine Seeger, Helen Booler, Philippe Valmaggia, Ken Kawamoto, Qayim Kaba, Nadja Inglin, Konstantinos Balaskas, Catherine Egan, Adnan Tufail, Hendrik P. N. Scholl, Pascal W. Hasler, Nora Denk
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Abstract The fovea is a depression in the center of the macula and is the site of the highest visual acuity. Optical coherence tomography (OCT) has contributed considerably in elucidating the pathologic changes in the fovea and is now being considere
Externí odkaz:
https://doaj.org/article/2039a0e81647468583b9864b2cfc5246
Autor:
Andrew G. Polson, Peter S. Dragovich, Jack D. Sadowsky, Thomas Pillow, Melissa M. Schutten, Rebecca K. Rowntree, Peter Yan, Kyu Hong, Montserrat Carrasco-Triguero, Fiona Zhong, Helen Booler, Douglas Leipold, Geoffrey del Rosario, Bing Zheng, Donna W. Lee, Shang-Fan Yu
We are interested in developing a second generation of antibody–drug conjugates (ADCs) for the treatment of non-Hodgkin lymphoma (NHL) that could provide a longer duration of response and be more effective in indolent NHL than the microtubule-inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76e0b06cd0c060e113446fb4818a68f5
https://doi.org/10.1158/1535-7163.c.6542727.v1
https://doi.org/10.1158/1535-7163.c.6542727.v1
Autor:
Andrew G. Polson, Peter S. Dragovich, Jack D. Sadowsky, Thomas Pillow, Melissa M. Schutten, Rebecca K. Rowntree, Peter Yan, Kyu Hong, Montserrat Carrasco-Triguero, Fiona Zhong, Helen Booler, Douglas Leipold, Geoffrey del Rosario, Bing Zheng, Donna W. Lee, Shang-Fan Yu
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e6caa4c5b88f15663e735cef0c387c4
https://doi.org/10.1158/1535-7163.22520694
https://doi.org/10.1158/1535-7163.22520694
Autor:
Whitney Shatz, Philip E Hass, Nikhil Peer, Maciej T Paluch, Craig Blanchette, Guanghui Han, Wendy Sandoval, Ashley Morando, Kelly M Loyet, Vladimir Bantseev, Helen Booler, Susan Crowell, Amrita Kamath, Justin M Scheer, Robert F Kelley
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0218613 (2019)
Innovative protein engineering and chemical conjugation technologies have yielded an impressive number of drug candidates in clinical development including >80 antibody drug conjugates, >60 bispecific antibodies, >35 Fc-fusion proteins and >10 immuno
Externí odkaz:
https://doaj.org/article/82a56a7b258c43e885de3b136fc2e95b
Autor:
Doha Naga, Smaragda Dimitrakopoulou, Sonia Roberts, Elisabeth Husar, Susanne Mohr, Helen Booler, Eunice Musvasva
In-vivo toxicity assessment is an important step prior to clinical development and is still the main source of data for overall risk assessment of a new molecular entity (NCE). All in-vivo studies are performed according to regulatory requirements an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aff8858ec323ce04a8a3997df28584a7
https://doi.org/10.1101/2022.08.06.503048
https://doi.org/10.1101/2022.08.06.503048
Autor:
Kyu Hong, Peter S. Dragovich, Bing Zheng, Douglas D. Leipold, Thomas H. Pillow, Andrew Polson, Peter Yan, Shang-Fan Yu, Montserrat Carrasco-Triguero, Melissa Schutten, Geoffrey Del Rosario, Rebecca K. Rowntree, Fiona Zhong, Jack Sadowsky, Donna W. Lee, Helen Booler
Publikováno v:
Molecular Cancer Therapeutics. 20:340-346
We are interested in developing a second generation of antibody–drug conjugates (ADCs) for the treatment of non-Hodgkin lymphoma (NHL) that could provide a longer duration of response and be more effective in indolent NHL than the microtubule-inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05119968230e699eb33bb8cdb1d79112
https://doi.org/10.1158/1535-7163.mct-20-0046
https://doi.org/10.1158/1535-7163.mct-20-0046
Autor:
Denise E. de Almeida Nagata, Jennifer Vogt, Roxanne Andaya, Helen Booler, Vladimir Bantseev, Chris Schuetz, Chris Lawson, Debby P. Chang
Publikováno v:
Toxicologic Pathology. 49:621-633
Sustained drug delivery formulations are developed to reduce dose frequency while maintaining efficacy of intravitreal (ITV) administered therapeutics. Available safety data for components novel to the eye’s posterior segment may be limited, requir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b38c0c483e214753e082c3220193b0a
https://doi.org/10.1177/0192623320971571
https://doi.org/10.1177/0192623320971571
Autor:
Typhaine Lejeune, Brian Short, Jaqueline Brassard, Krishna Yekkala, Margarita M. Gruebbel, Cindy A. Farman, Bindu Bennet, Oliver C. Turner, Steven D. Sorden, Kenneth A Schafer, Elke-Astrid Atzpodien, Helen Booler, George L. Foley, Meg Ferrell Ramos
Publikováno v:
Toxicologic pathology. 50(2)
A Working Group of the Society of Toxicologic Pathology’s Scientific and Regulatory Policy Committee conducted a technical and scientific review of current practices relating to the fixation, trimming, and sectioning of the nonrodent eye to identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8534718ecfa0edfef4e0b09dec1d2a8
https://pubmed.ncbi.nlm.nih.gov/34693851
https://pubmed.ncbi.nlm.nih.gov/34693851
Autor:
Gautham K. Rao, Stephen P. Schauer, Edmond Teng, Joseph Bravo, Reina N. Fuji, Andrea Pfeifer, Yong Ying, Kimberly Scearce-Levie, Jessica Couch, Hilda Solanoy, Paul T. Manser, Andreas Muhs, Han Lin, Daniela Bumbaca Yadav, Oded Foreman, Dongping He, James A. Ernst, Flavia Brunstein, Hai Ngu, Michael C. M. Kwok, Maria Pihlgren, Oskar Adolfsson, Mira Blendstrup, William B. Smith, Priya Chandra, Akash Datwani, Michael Keeley, Danielle DiCara, Robert Brendza, Yanmei Lu, Julien Lafrance-Vanasse, Corinne Foo-Atkins, Jasvinder K. Atwal, Isidro Hötzel, Seung-Hye Lee, Kristin R. Wildsmith, Ruby Chan, Helen Booler, Rich Erickson, Barthélemy Demeule, Geoffrey A. Kerchner, Wilman Luk, Gai Ayalon
Publikováno v:
Science Translational Medicine. 13
Tau has become an attractive alternative target for passive immunotherapy efforts for Alzheimer's disease (AD). The anatomical distribution and extent of tau pathology correlate with disease course and severity better than other disease markers to da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c8226f0212aa58c81fd5ec5abd2b2f7
https://doi.org/10.1126/scitranslmed.abb2639
https://doi.org/10.1126/scitranslmed.abb2639